

AMENDMENTS TO THE CLAIMS

1. **(canceled)** ~~A small interfering RNA (siRNA) comprising at least one modified base, wherein the modified base is capable of enhancing single nucleotide discrimination between a first target having 1, 2, 3 or more point mutations relative to a second target.~~
2. **(currently amended)** A small interfering RNA (siRNA) capable of single nucleotide discrimination between a first and second allele, the first allele having 1, 2, 3 or more point mutations relative to the second allele, wherein the siRNA comprises a sense strand and an antisense strand, wherein the antisense strand comprises at least one a modified base positioned opposite at least one point mutation in the first allele, and wherein the modified base is capable of enhancing binding interactions between the siRNA and mRNA encoded by the first allele when compared with binding interactions between the siRNA and mRNA encoded by the second allele.
3. **(original)** A small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand comprises a sequence homologous to a region of a mutant allele encoding a gain-of-function mutant protein, said region comprising one or more point mutations, and wherein the antisense strand comprises a sequence comprising one or more modified bases positioned opposite the point mutations, such that the siRNA directs allele-specific cleavage of a mRNA encoded by the mutant allele.
4. **(currently amended)** The siRNA of claims 2 or 3 ~~any one of claims 1-3~~, wherein the modified base is selected from the group consisting of 5-bromo-uridine, 5-bromo-cytidine, 5-iodo-uridine, 5-iodo-cytidine, 2-amino-purine, 2-amino-allyl-purine, 6-amino-purine, 6-amino-allyl-purine, 2, 6-diaminopurine and 6-amino-8-bromo-purine.
5. **(original)** The siRNA of claim 4, wherein the modified base is 5-bromo-uridine or 5-iodo-uridine.
6. **(original)** The siRNA of claim 5, wherein the point mutation is an adenine.

7. **(original)** The siRNA of claim 4, wherein the modified base is 2,6-diaminopurine.
8. **(original)** The siRNA of claim 7, wherein the point mutation is a thymine.
9. **(original)** The siRNAi of claim 3, which targets an allelic point mutation within a gene correlated with a disorder selected from the group consisting of amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease.
10. **(currently amended)** The siRNA of claims 2 or 3 ~~any one of claims 1-3~~, which is between about 10 and 50 residues in length.
11. **(currently amended)** The siRNA of claims 2 or 3 ~~any one of claims 1-3~~, which is between about 15 and 45 residues in length.
12. **(currently amended)** The siRNA of claims 2 or 3 ~~any one of claims 1-3~~, which is between about 20 and 40 residues in length.
13. **(currently amended)** The siRNA of claims 2 or 3 ~~any one of claims 1-3~~, which is between about 18-25 residues in length.
14. **(currently amended)** A therapeutic composition, comprising the siRNA of claims 2 or 3 ~~any one of claims 1-3~~ and a pharmaceutically acceptable carrier.
15. **(currently amended)** A host cell comprising the siRNAi of claims 2 or 3 ~~any one of claims 1-3~~.
16. **(original)** The host cell of claim 15, which is mammalian cell.
17. **(original)** The host cell of claim 15, which is a human cell.
18. **(withdrawn-currently amended)** A method of selectively targeting in a cell a first allele having 1, 2, 3 or more mutations relative to a second allele, the method comprising

contacting the cell with an siRNA according to claims 2 or 3 ~~any one of claims 1-3~~ having a sequence specific for the first allele, such that the first allele is selectively targeted.

19. **(withdrawn-currently amended)** A method of inhibiting expression of a target allele in a cell comprising at least two different alleles of a gene, the method comprising introducing into the cell an siRNA according to claims 2 or 3 ~~any one of claims 1-3~~ having a sequence specific for the target allele, said siRNA being introduced in an amount sufficient for degradation of a mRNA encoded by the target allele to occur, thereby inhibiting expression of the target allele.

20. **(withdrawn)** The method of claim 19, wherein the target allele is correlated with a disease or disorder associated with a dominant gain-of-function mutation.

21. **(withdrawn)** The method of claim 20, wherein the disease or disorder is chosen from the group consisting of amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease.

22. **(withdrawn)** The method of claim 19, wherein the expression is inhibited by at least 10%.

23. **(withdrawn)** A cell obtained by the methods of claim 19.

24. **(withdrawn)** cell of claim 23, which is of mammalian origin.

25. **(withdrawn)** A cell of claim 24, which is of human origin.

26. **(withdrawn)** A cell of claim 24, which is an embryonic stem cell.

27. **(withdrawn-currently amended)** A method of activating allele-specific RNA interference (RNAi) in an organism comprising at least two different alleles of a gene, the method comprising administering to the organism the siRNA of claims 2 or 3 ~~any one of claims 1-3~~ having a sequence specific for the target allele, said siRNA being administered in

an amount sufficient for degradation of the target allele mRNA to occur, thereby activating allele-specific RNAi in the organism.

28. **(withdrawn)** The method of claim 27, wherein the target allele is correlated with a disease or disorder associated with a dominant gain-of-function mutation.

29. **(withdrawn)** The method of claim 28, wherein the disease or disorder is chosen from the group consisting of amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease.

30. **(withdrawn)** The organism obtained by the method of claim 27.

31. **(withdrawn-currently amended)** A method of treating a subject having a disease or disorder correlated with the presence of a dominant gain-of-function mutant allele, the method comprising administering to the subject an siRNA of claims 2 or 3 ~~any one of claims 1-3~~ having a sequence specific for the mutant allele, said siRNA being administered in an amount sufficient for degradation of a mRNA encoded by the mutant allele to occur, thereby treating the subject.

32. **(withdrawn)** The method of claim 31, wherein the disease or disorder is chosen from the group consisting of amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease.

33. **(withdrawn)** The method of claim 31, wherein the siRNA is targeted to the gain-of-function mutation.

34. **(withdrawn)** The method of claim 31, wherein the mutant allele comprises one or more point mutations.